Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensifentrine CAT Score Study in COPD
NCT06460493Phase 3Completed
- Sponsor
- Verona Pharma
- Start
- Jun 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ensifentrine in chronic obstructive pulmonary disease (COPD), sponsored by Verona Pharma. Primary endpoint: Proportion of CAT Score Responders at 12 weeks. Started Jun 2024; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06460493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06460493.